Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 5/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TPH1 | P17752 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116002 | 0.93 | MRGPRX4 (0.53) | MAPTNPC1RAB9AMRGPRX4PTGER1 | |
| SCHEMBL5130507 | 0.90 | MAPT (0.47) | MAPTNPC1RAB9AMRGPRX4PTGER1 | |
| SCHEMBL5130014 | 0.90 | MAPT (0.49) | MAPTNPC1RAB9AMRGPRX4PTGER1 | |
| SCHEMBL5124847 | 0.90 | MAPT (0.59) | MAPTNPC1RAB9AMRGPRX4PTGER1 | |
| SCHEMBL5128854 | 0.90 | MAPT (0.46) | MAPTNPC1RAB9AMRGPRX4PTGER1 | |
| SCHEMBL5125052 | 0.90 | MRGPRX4 (0.48) | MAPTNPC1RAB9AMRGPRX4PTGER1 | |
| SCHEMBL4723594 | 0.89 | PTGER1 (0.56) | MAPTNPC1RAB9AMRGPRX4PTGER1 | |
| SCHEMBL5125557 | 0.89 | PTGER1 (0.48) | MAPTNPC1RAB9AMRGPRX4PTGER1 | |
| SCHEMBL5129813 | 0.88 | PTGER1 (0.58) | MAPTNPC1RAB9APTGER1ALDH1A1 | |
| SCHEMBL5125898 | 0.88 | MAPT (0.52) | MAPTNPC1RAB9APTGER1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | GLAXO GROUP LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207708-A1 | Oxazole and Thiazole Compounds and Their Use in the Treatment of Pge2 Mediated Disorders | PTGER1, PTGER2, PTGER4 | MAPT 4703/4885NPC1 3020/4885RAB9A 4378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.